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ABSTRACT 
For quite some time, glaucoma has been regarded as more than just intraocular pressure [IOP] elevation. 
Significant contribution to this conceptual improvement has risen from a better understanding of ocular 
blood flow, vessel wall integrity and certain advanced ideas in neuroophthalmology, for example 
neuroprotection. Transforming growth factor–β (TGF-β) molecule, its inhibitors and antagonists have been 
increasingly researched as possible new anti-glaucoma drugs for its many, pleiotropic, effects. Among those 
effects, enhancing fibrosis is one of the most apparent, but certain members of this cytokine’s superfamily 
act as anti-fibrotics. Recent scientific efforts strongly support pushing back the frontier of conventional 
medical treatment. Current medical approaches already use effects on blood flow and neuronal 
quiescence, with significant systemic side-effects. Endeavours on the ophthalmologic exploitation of 
selected, favourable effects of pleiotropic TGF-βs could promote TGF-β, its inhibitors or specific antibodies 
as new, ideal drugs in glaucoma therapy. 
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INTRODUCTION  
Glaucoma, a progressive optic neuropathy [1,2], is the second 
leading cause of vision loss. The vascular theory of glaucoma 
considers optic neuropathy as a consequence of blood supply 
that is jeopardised by a reduced ocular blood flow [3,4]. Ocular 
blood flow is an extremely complex process, as metabolic 
needs follow changes in visual function [5-10].  
In vitro studies have suggested that transforming growth 
factor-β [TGF-β] signalling pathways regulate angiogenesis 
[11,12]. This originates from ALK-1 [13] and -5. Both act 
through receptor-regulated SMADs, though via different 
methods [14]. Mostly, SMADs are bone morphogenetic protein 
[BMP]-dependent, and are activated in various animal tissues 
[15]. In pulmonary or hepatic fibrosis, systemic sclerosis, 
glomerulosclerosis or in dermal scarring, there is noticeable 
evidence that TGF-β mediates a pathological increase in 
extracellular matrix deposition [16-20]. Although not all 
members of this superfamily act as pro-fibrotics [12,15,16,20], 
TGF-β was found to increase extracellular matrix proteins in the 
optic nerve [21], and affect rabbit sub-conjunctival fibroblasts 
[22].   
Endothelium 
BMPs play an important role in endothelial cell [EC] function 
[23-26]. Interestingly, different ECs are differently susceptible 
to different isoforms of TGF-β. BMP-4 and -6 [members of the 
TGF-β superfamily] promote EC migration and proliferation 
 
 
MEHDI Ophthalmology Journal 2012; Vol. 1, No 3     
 
58 REVIEW ON HYPOTHETICAL IMPLEMENTING TGF-Β FAMILY MEMBERS IN GLAUCOMA THERAPY 
[27], while BMP-9 is a circulating vascular quiescence factor 
[28]. Vascular endothelium releases different vasoactive factors 
that regulate the microcirculation [29,30]. Previously, BMP-2, -
4, and -7 have been reported to bind ALK1 receptors and EC, 
which are targets for certain ligands of the BMP members of 
the TGF family [23]. Vascular endothelial dysfunction is a 
frequent basis of many diseases [31,32]. Dysfunction in the 
endothelium can influence the vessel’s diameter and 
resistance.  
Reduced levels of nitric oxide [NO] can result in decreased 
vasodilatation and increased vasoconstriction [33-35] 
connected consecutively by a decrease in nitrosylation [36] and 
fragmentation of DNA, all of which lead to apoptosis [37]. Low 
levels of nitric oxide reduce blood flow as in glaucoma. 
Compromised availability of NO as well as an imbalance 
between NO and endothelin-1 [ET-1] have been reported in 
glaucoma patients [38]. Patients with normal-tension glaucoma 
have increased plasma, and those with open angle glaucoma 
have aqueous humor levels of ET-1 [39,40]. Vasoconstriction 
inevitably leads to hypoxia, which makes it reasonable to 
suppose that various cytokines may be up-regulated in 
glaucoma [41,42]. 
Ocular Blood Flow 
Researchers have long reported that patients with open-angle 
glaucoma exert altered blood flow in retinal, choroid, and 
retro-bulbar circulation [5-9,43]. An alteration in the eye blood 
supply can be further correlated to vascular endothelial 
dysfunction [31,32]. The narrowing of blood vessels increases 
resistance to flow distally, which leads to hypoxia. Several 
population-based studies documented retinal vascular 
narrowing. Structural changes might increase flow resistance, 
or might result in functional dysregulation of the vascular 
width. Reduction in the blood flow is not only limited to the eye 
but to the orbit and even the periphery. In some patients, 
blood flow reduction precedes glaucoma [44]. Intraocular 
pressure [IOP] alone is unlikely to cause the disruption of ocular 
blood flow more distinctly in normal-tension patients than 
high-tension ones. Reduced perfusion pressure could result in 
increased IOP or decreased blood pressure [44-46], and the 
increased viscosity of blood can be a result of a blood dyscrasia. 
Neuroprotection of TGF-β 
Due to its pleiotropy, the beneficial effect of TGF-β on vascular 
integrity has been easy to understand. That effect is not 
impossible to link to its many different functions, like local 
neuroprotective humoral agents or mediator in embryogenesis. 
The objective is to connect its vascular quiescence to the 
established endothelial NO production in order to influence 
cerebral perfusion [48]. Furthermore, TGF-β as the vascular-
integrity guard ensures the preservation of the vessel wall, thus 
eliminating factors required for scarring. TGF-β mRNA is 
elevated for at least a week after a stroke and clearly exerts a 
neuroprotective role [48]. Nevertheless, in order to exploit the 
therapeutic properties of TGF-β, any additional roles in the 
brain after stroke should be clearly understood. However, the 
acute abolition of blood supply, as in strokes, should not be 
compared to long-lasting, chronic diseases, like glaucoma. 
Moreover, not all TGF-β members exhibit pro-fibrotic actions.  
Thanks to the neuroprotective effects of TGF-β [47-49], it is 
considered a future important target for therapy following a 
stroke. The precise function of increased TGF-β after stroke is 
unknown and due to its pleiotropic nature, it might well 
modulate NO production by ECs, orchestrate glial scarring, or 
function as a significant immune system regulator. Even NO is 
potentially neurotoxic, due to the reaction with superoxide 
anions, which produce reactive free radical species. 
  
HYPOTHESIS 
The ideal anti-glaucoma drug would prevent cell death of the 
retina with no adverse effects. However, a more realistic ideal 
drug would be one that reduces IOP, and reaches the retina in 
appropriate amounts to reduce retinal cell death, even if 
applied topically [2,45,50]. A variety of agents may act on 
growth factors, including TGF-β. Employing antibodies against 
the TGF-β superfamily members that are involved in 
angiogenesis and vessel quiescence as a treatment option for 
glaucoma is not new. One of the theoretical advantages of the 
human TGF-β2 antibody [which is the predominant form in the 
aqueous] is that it only acts if there is TGF-β2 in the wound, 
unlike an anti-metabolite [51]. Even if all of the above is 
neglected, the vasoconstrictive effect of ET-1, mediated by TGF-
β-stimulated ALK-5 remains an open option. The employment 
of inhibitors of TGF-β in glaucoma therapy is also not new. N-
[3', 4'—dimethoxycinnamoyl]anthranilic acid inhibits TGF-β 
activity and has anti-scarring effects in the body and the eye 
[52]. Interferon-α, an anti-fibrotic cytokine, has been shown to 
reduce the scarring activity of fibroblasts, although a clinical 
trial did not show it to be significantly better than current anti-
metabolites [53]. 
With respect to vascular theory on the aetiology of glaucoma, 
the possible involvement of the TGF-β signalling system in the 
treatment approach of glaucoma is hypothesised, regarding 
endothelial dysfunction, ocular blood flow and neuroprotective 
features of TGF-β. This should be based on the inhibition of the 
pathological accumulation of the extracellular matrix and the 
modulation of fibrotic mechanisms with new anti-fibrotic 
agents. Further confirmation is needed to elucidate whether 
the cross-talk of TGF-β with other pathway systems already 
employed in the therapy of glaucoma exists. Also, it is 
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important to fully understand any possible impact of any TGF-β 
superfamily members on complex pathophysiological 
mechanisms in glaucoma.  
 
DISCUSSION 
The vascular theory suggests that insufficient blood supply 
results in glaucoma. Conditions such as normal-tension 
glaucoma are among the chief strongholds to this theory. The 
reduction of ocular blood flow often precedes glaucomatous 
damage. Other parts of the body in glaucoma patients might 
also exert reduced blood flow, e.g. the extremities. 
Additionally, there is an increased prevalence of ischaemic 
lesions in other organs of the body that result in hearing 
problems, heart attacks, and small strokes in these patients. 
Vascular dysregulation in arteriosclerosis leads to low 
profusion. Glaucoma is only faintly related to arteriosclerosis. 
The relationship between treatment with antihypertensive 
medication in glaucoma-free subjects and structural changes in 
the optic disc was established by epidemiologic cross-sectional 
studies [44,54]. Increased IOP is, to some extent, associated 
with high blood pressure, but glaucoma is linked to low blood 
pressure [44]. Finally, patients with a decrease in blood 
pressure while sleeping may have a higher risk of glaucoma 
progression. Low perfusion pressure is compensated by auto-
regulation, ensuring normal perfusion. There are indications 
that this auto-regulation is altered in some patients with 
glaucoma.    
Vascular conditions, such as Raynaud’s disease, apnoea during 
sleep [55], and migraine headaches, are all associated with 
glaucoma. Raynaud’s disease may be an indicator for normal-
tension glaucoma. Sleep apnoea is not necessarily a vascular 
condition, although decreased breathing means diminutions in 
the intake of oxygen. Migraine headaches may indicate 
decreased blood flow to areas of the brain. Atrial fibrillation, 
possibly causing irregular flow states, is also associated. Loss of 
blood, haemorrhage, or the necessity for a blood transfusion, 
can also cause glaucomatous defects in the optic nerve and 
visual field [56,57].  
It is almost certain that obesity would be risk factor for both 
increased IOP and for arteriosclerosis. High cholesterol is also a 
risk factor for increased IOP, but not for normal-tension 
glaucoma. Normal-tension glaucoma patients tend to have a 
lower body mass index [58], and smoking and diabetes are 
associated with increased IOP but not with glaucoma. Men tend 
to have more, and earlier, arteriosclerotic plaques, but women 
are actually at a higher risk for normal-tension glaucoma 
[59,60].   
Indirect signs of altered blood flow in the eye include changes 
in conjunctival capillaries. Something less evident, however, is 
local vasoconstriction in the retina. An increased frequency of 
optic disc haemorrhages and gliosis-like alterations are 
indicators for altered blood flow. Disc haemorrhages occur in all 
stages of the disease and are more frequent in normal-tension 
glaucoma [61].    
Since the heart cycle significantly reflects the arterial blood 
flow to the eye, the volume of all ocular sheets [especially of 
the choroid] and the IOP are highest during systole [62]. A 
connection of vasculature and glaucoma should be sought in a 
decrease of blood flow [5-9,31,32,43]. Decreased blood influx 
to the optic nerve might be either due to decreased blood 
pressure, narrowing of the vessels or due to increased IOP 
[41,44]. Decreased circulation follows decreased blood flow or 
decreased perfusion, which could result in increased optic 
nerve damage that is comparable to ischaemia of the heart or 
brain [30,41]. 
Medications could be used to lower IOP. Several different 
classes of medications are used in glaucoma management 
[63,64]. None of these is unfettered with both local and 
systemic side-effects. If they occur, the patient must be willing 
either to tolerate these, or to communicate with the treating 
physician to improve the drug regimen. Poor compliance with 
treatment regimes and follow-up visits is a major reason for 
disease progression to blindness in glaucoma patients. Patient 
education and communication must be the target of any 
successful therapy. 
Various cytokines are released as a response to tissue injury 
[65], i.e. a breakdown in the blood—aqueous barrier [66], 
which may not be clinically visible. This feature was established 
for numerous agents active on a cellular level, including 
cytokines and growth factors. Because of their significance, 
tissue scarring, inhibition or antagonism of this action was the 
focus of glaucoma therapy.  
Therefore, in the therapy of glaucoma, fibrinolytic agents have 
had their place [67] as they may lower IOP, however, a risk of 
further extra- and intraocular haemorrhage should not be 
neglected [68]. Fibroblast activation has also been a target of 
anti-glaucoma therapy [69]. 
However, considering all of these molecules, they may have a 
longer-term stimulatory effect on wound healing when 
breaking down. The prevention of clotting may be a more 
promising avenue. 
Gingko biloba extract is one of the supplements that has been 
given to patients most frequently [70,71], and may increase 
peripheral blood flow [72]. A diet high in antioxidants has been 
believed to reduce the risk of glaucoma [73]. However, none of 
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the supplements have been proven in randomised controlled 
trials.   
It is possible that, irrespective of IOP, various strains can 
damage the connective tissue of the optic nerve and axons. 
Reduced ocular blood flow, perhaps adjoined by underlying 
vascular disease, is directly involved in the pathophysiology of 
glaucoma. Dysregulation or an inadequate vasomotor activity in 
some glaucoma patients is often combined with widening 
vessels in neighbouring tissues. This decreases the adjusting 
capacity for the different flow states in decreasing blood flow 
to the nerve, and thereby causes the subsequent progression of 
the glaucoma.   
Certain carbonic anhydrase inhibitors have been shown to 
possibly increase ocular perfusion and produce a short-term 
improvement in the visual field [56,63]. The potential 
neuroprotective effects of various topical and systemic 
medications are also being investigated. In this way, the role of 
TGF-β, its inhibition or deleting its effect by coupling with 
polyclonal antibodies, needs to be viewed and evaluated as a 
possible ideal drug for glaucoma therapy. 
 
CONCLUSIONS 
There is a need to improve the technology for the 
measurement of ocular blood flow, since studies are still at the 
stage of simply lowering IOP [45]. Next, a requirement exists for 
establishing data by comparing glaucoma patients to normal 
individuals and to identify subgroups of those with glaucoma. 
After setting out all of the parameters, it will be possible to 
correlate these findings with optic nerve and visual field 
damage. That might, perhaps target vascular dysregulation to 
treat glaucoma patients. At present, no medication exists to 
increase ocular perfusion.   
Neuroprotection is appreciated for the very absence of the 
need to treat the cause of the disease. Neuroprotective 
medications are, however, still being explored, and could 
provide protection to such neurons that continue to remain at 
risk. Neuroprotection attempts to address the common way of 
an insult, regardless of its cause. 
The neuroprotective role of α2-adrenergic receptor agonists in 
the retina seems to be gaining importance in the treatment of 
glaucoma. However, the exact mechanism [supposedly 
transactivation] by which an α2-adrenergic agonist exhibits 
neuroprotection of neuronal elements in the retina still remains 
to be proven [74]. 
Endothelial integrity, blood flow, and glaucoma are active and 
dynamic fields that will, in the future, given adequate attention, 
interest, and scientific research, produce results that will help 
treat and withhold the progression of glaucoma.    
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